President and COO of NuVasive Inc. (NUVA, Financial) Keith Valentine sells 6,265 shares of NUVA on 10/20/2009 at an average price of $43.44 a share.
NUVASIVE is a medical device company focused on the design development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery or MAS as well as a growing offering of cervical and motion preservation products. Nuvasive Inc. has a market cap of $1.44 billion; its shares were traded at around $40.06 with a P/E ratio of 152.6 and P/S ratio of 5.8.
NUVASIVE is a medical device company focused on the design development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery or MAS as well as a growing offering of cervical and motion preservation products. Nuvasive Inc. has a market cap of $1.44 billion; its shares were traded at around $40.06 with a P/E ratio of 152.6 and P/S ratio of 5.8.
Insiders' Positions with NUVA
- Sell:: CEO and Chairman on 10/07/2009 Alexis V Lukianov sold 20,000 shares of NUVA stock at the average price of 41.66, the price of the stock has decreased by 3.84% since
- Sell:: CEO and Chairman on 09/09/2009 Alexis V Lukianov sold 20,000 shares of NUVA stock at the average price of 39.11, the price of the stock has increased by 2.43% since
- Sell:: CEO and Chairman on 08/07/2009 Alexis V Lukianov sold 20,000 shares of NUVA stock at the average price of 42.43, the price of the stock has decreased by 5.59% since
- Sell:: CEO and Chairman on 07/08/2009 Alexis V Lukianov sold 20,000 shares of NUVA stock at the average price of 39.88, the price of the stock has increased by 0.45% since
- Sell:: CEO and Chairman on 07/08/2009 Alexis V Lukianov sold 20,000 shares of NUVA stock at the average price of 39.88, the price of the stock has increased by 0.45% since
Insiders' Positions with NUVA
- Sell:: CFO and Executive VP on 10/14/2009 Kevin C Oboyle sold 3,316 shares of NUVA stock at the average price of 41.81, the price of the stock has decreased by 4.19% since
- Sell:: CFO and Executive VP on 09/15/2009 Kevin C Oboyle sold 2,185 shares of NUVA stock at the average price of 42.25, the price of the stock has decreased by 5.18% since
- Sell:: CFO and Executive VP on 09/15/2009 Kevin C Oboyle sold 3,402 shares of NUVA stock at the average price of 42.25, the price of the stock has decreased by 5.18% since
- Sell:: CFO and Executive VP on 09/14/2009 Kevin C Oboyle sold 8,152 shares of NUVA stock at the average price of 41.99, the price of the stock has decreased by 4.6% since
- Sell:: CFO and Executive VP on 08/14/2009 Kevin C Oboyle sold 2,180 shares of NUVA stock at the average price of 40.97, the price of the stock has decreased by 2.22% since
Insiders' Positions with NUVA
- Sell:: SVP and General Counsel on 10/09/2009 Jason Hannon sold 1,675 shares of NUVA stock at the average price of 41.58, the price of the stock has decreased by 3.66% since
- Sell:: SVP and General Counsel on 09/29/2009 Jason Hannon sold 11,742 shares of NUVA stock at the average price of 40.19, the price of the stock has decreased by 0.32% since
- Sell:: Senior V.P., U.S. Sales on 09/25/2009 Jeffrey P Rydin sold 1,406 shares of NUVA stock at the average price of 39.13, the price of the stock has increased by 2.38% since
- Sell:: EVP, Marketing and Development on 09/23/2009 Patrick Miles sold 3,908 shares of NUVA stock at the average price of 40.36, the price of the stock has decreased by 0.74% since
- Sell:: President and COO on 09/21/2009 Keith Valentine sold 6,152 shares of NUVA stock at the average price of 40.96, the price of the stock has decreased by 2.2% since
